Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Timapiprant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 known ✓ | Q9Y5Y4 | 20/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 2/20 | 1.00 |
| ▸ | PTGIR | P43119 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Timapiprant SCHEMBL29379400 | 1.00 | PTGDR2 (1.00) | PTGDR2PTGDRPTGIRCYP1A2CYP3A4 | |
| Timapiprant SCHEMBL29648518 | 1.00 | PTGDR2 (1.00) | PTGDR2PTGDRPTGIRCYP1A2CYP3A4 | |
| SCHEMBL1786702 | 0.92 | PTGDR2 (0.85) | PTGDR2PTGDRPTGIRCYP1A2CYP3A4 | |
| SCHEMBL16558834 | 0.90 | PTGDR2 (0.82) | PTGDR2PTGDRPTGIRCYP1A2CYP3A4 | |
| SCHEMBL18456932 | 0.90 | PTGDR2 (0.81) | PTGDR2PTGDRPTGIR | |
| SCHEMBL22167497 | 0.89 | PTGDR2 (0.80) | PTGDR2PTGDRPTGIRCYP1A2CYP3A4 | |
| SCHEMBL3260069 | 0.88 | PTGDR2 (0.79) | PTGDR2PTGDRPTGIRCYP1A2CYP3A4 | |
| SCHEMBL1786634 | 0.88 | PTGDR2 (0.78) | PTGDR2PTGDRPTGIR | |
| SCHEMBL1785206 | 0.87 | PTGDR2 (0.77) | PTGDR2PTGDRPTGIR | |
| SCHEMBL1782474 | 0.87 | PTGDR2 (0.77) | PTGDR2PTGDRPTGIRCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345897-A1 | AMORPHOUS (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYL-INDOL-1-YL)-ACETIC ACID | Atopix Therapeutics Limited (GB) | 2018-07-11 | — | — | EP | claimed |
| EP-3083557-B1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED (INDOL-1-YL)-ACETIC ACID ESTERS | ATOPIX THERAPEUTICS LTD (GB) | 2017-11-29 | — | — | EP | claimed |
| US-9828359-B2 | Process for the preparation of 3-substituted (indol-1-yl)-acetic acid esters | ATOPIX THERAPEUTICS LIMITED (GB) | 2017-11-28 | — | — | US | claimed |
| EP-2697215-B1 | AMORPHOUS (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYL-INDOL-1-YL)-ACETIC ACID | ATOPIX THERAPEUTICS LTD (GB) | 2017-11-22 | — | — | EP | claimed |
| US-20170305879-A1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED (INDOL-1-YL)-ACETIC ACID ESTERS | ZACH SYSTEM SPA (IT) | 2017-10-26 | — | — | US | claimed |
| EP-3083557-A1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED (INDOL-1-YL)-ACETIC ACID ESTERS | Atopix Therapeutics Limited (GB) | 2016-10-26 | — | — | EP | claimed |
| CN-104114548-B | The preparation method of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic ester | OXAGEN LTD. (GB) | 2016-01-20 | — | — | CN | claimed |
| EP-2791129-B1 | PROCESS FOR THE PREPARATION OF (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYL-INDOL-1-YL)-ACETIC ACID ESTERS | ATOPIX THERAPEUTICS LTD (GB) | 2015-10-07 | — | — | EP | claimed |
| US-9102658-B2 | Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-y1)-acetic acid esters | ATOPIX THERAPEUTICS LIMITED (GB) | 2015-08-11 | — | — | US | claimed |
| WO-2015092372-A1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED (INDOL-1-YL)-ACETIC ACID ESTERS | ATOPIX THERAPEUTICS LIMITED (GB) | 2015-06-25 | — | — | WO | claimed |
| EP-1682121-B1 | USE OF CRTH2 ANTAGONIST COMPOUNDS IN THERAPY | OXAGEN LTD (GB) | 2009-08-12 | — | — | EP | claimed |
| WO-2009063215-A2 | USE OF CRTH2 ANTAGONIST COMPOUNDS | OXAGEN LIMITED (GB) | 2009-05-22 | — | — | WO | claimed |
| WO-2009063202-A2 | USE OF CRTH2 ANTAGONIST COMPOUNDS | OXAGEN LIMITED (GB) | 2009-05-22 | — | — | WO | claimed |
| US-20090018139-A1 | Treatment of CRTH2-mediated diseases and conditions | OXAGEN LIMITED (GB) | 2009-01-15 | — | — | US | claimed |
| US-20090018138-A1 | Treatment of CRTH2-mediated diseases and conditions | OXAGEN LIMITED (GB) | 2009-01-15 | — | — | US | claimed |
| EP-2004602-A1 | SALTS WITH CRTH2 ANTAGONIST ACTIVITY | Oxagen Limited (GB) | 2008-12-24 | — | — | EP | claimed |
| EP-1856094-A1 | MICROCRYSTALLINE (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYL-INDOL-1-YL)ACETIC ACID | Oxagen Limited (GB) | 2007-11-21 | — | — | EP | claimed |
| WO-2007107772-A1 | SALTS WITH CRTH2 ANTAGONIST ACTIVITY | OXAGEN LIMITED (GB) | 2007-09-27 | — | — | WO | claimed |
| WO-2006092579-A1 | MICROCRYSTALLINE ( 5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYL-INDOL-1-YL) ACETIC ACID | OXAGEN LIMITED (GB) | 2006-09-08 | — | — | WO | claimed |
| US-20050119268-A1 | Treatment of CRTH2-mediated diseases and conditions | OXAGEN LIMITED (GB) | 2005-06-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018138-A1 | Treatment of CRTH2-mediated diseases and conditions | PTGDR2, PTGER2, PTGES2 | PTGDR2 1/4885PTGDR 4/4885PTGIR 18/4885 |
| US-20050119268-A1 | Treatment of CRTH2-mediated diseases and conditions | PTGDR2, PTGER2, PTGES2 | PTGDR2 1/4885PTGDR 4/4885PTGIR 18/4885 |
| US-20090018139-A1 | Treatment of CRTH2-mediated diseases and conditions | PTGDR2, PTGER2, PTGES2 | PTGDR2 1/4885PTGDR 4/4885PTGIR 18/4885 |
| US-20170305879-A1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED (INDOL-1-YL)-ACETIC ACID ESTERS | IDO1, IDO2, SI | PTGDR2 1790/4885PTGDR 1547/4885PTGIR 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.